Clinical Trials /

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

NCT02800486

Description:

Primary brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with median survival at approximately 12 months. Glioma is the most common form of primary brain cancer, afflicting approximately 7,000 patients in the United States each year. These highly malignant cancers remain a significant unmet clinical need in oncology. GBM often has a high expression of EFGR (Epidermal Growth Factor Receptor), which is associated with poor prognosis. Several methods of inhibiting this receptor have been tested, including monoclonal antibodies, vaccines, and tyrosine kinase inhibitors. The investigators hypothesize that in patients with recurring GBM, intracranial superselective intra-arterial infusion of Cetuximab (CTX), at a dose of 250mg/m2 in conjunction with hypofractionated radiation, will be safe and efficacious and prevent tumor progression in patients with recurrent, residual GBM.

Related Conditions:
  • Anaplastic Astrocytoma
  • Anaplastic Oligoastrocytoma
  • Glioblastoma
Recruiting Status:

Recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
  • Official Title: Phase II Trial of Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory Glioblastoma Multiforme, Anaplastic Astrocytoma, and Anaplastic Oligoastrocytoma

Clinical Trial IDs

  • ORG STUDY ID: HS16-0181
  • NCT ID: NCT02800486

Conditions

  • Glioblastoma
  • Anaplastic Astrocytoma
  • Anaplastic Oligoastrocytoma
  • Glioma
  • Brain Neoplasm
  • Brain Cancer
  • Brain Tumor
  • Brain Tumor, Recurrent
  • Brain Neoplasm, Malignant

Interventions

DrugSynonymsArms
Intra-arterial CetuximabIntra-arterial Cetuximab with Re-Irradiation
Intra-arterial MannitolIntra-arterial Cetuximab with Re-Irradiation

Purpose

Primary brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with median survival at approximately 12 months. Glioma is the most common form of primary brain cancer, afflicting approximately 7,000 patients in the United States each year. These highly malignant cancers remain a significant unmet clinical need in oncology. GBM often has a high expression of EFGR (Epidermal Growth Factor Receptor), which is associated with poor prognosis. Several methods of inhibiting this receptor have been tested, including monoclonal antibodies, vaccines, and tyrosine kinase inhibitors. The investigators hypothesize that in patients with recurring GBM, intracranial superselective intra-arterial infusion of Cetuximab (CTX), at a dose of 250mg/m2 in conjunction with hypofractionated radiation, will be safe and efficacious and prevent tumor progression in patients with recurrent, residual GBM.

Trial Arms

NameTypeDescriptionInterventions
Intra-arterial Cetuximab with Re-IrradiationExperimentalMannitol 20% 12.5ml over two minutes for blood brain barrier (BBB) disruption followed by Cetuximab administered intra-arterially for three doses at a dose of 250 mg/m2 combined with hypofractionated re-irradiation
  • Intra-arterial Cetuximab
  • Intra-arterial Mannitol

Eligibility Criteria

        Inclusion Criteria:

          -  Male or female patients of ≥18 years of age

          -  Patients with a documented histologic diagnosis of relapsed or refractory glioblastoma
             multiforme (GBM), anaplastic astrocytoma (AA) or anaplastic oligoastrocytoma (AOA)

          -  Patients with pathology confirmed histologic EGFR overexpression

          -  Patients must have at least one confirmed and evaluable tumor site.∗

             *A confirmed tumor site is one in which is biopsy-proven

          -  Patients must have a Karnofsky performance status ≥60% and an expected survival of ≥
             three months.

          -  No chemotherapy for two weeks prior to treatment under this research protocol and no
             external beam radiation for eight weeks prior to treatment under this research
             protocol

          -  Patients must have adequate hematologic reserve with WBC≥3000/mm3, absolute
             neutrophils ≥1500/mm3 and platelets ≥100,000/ mm3. Patients who are on Coumadin must
             have a platelet count of ≥150,000/ mm3

          -  Pre-enrollment chemistry parameters must show: bilirubin<1.5X the institutional upper
             limit of normal (IUNL); AST or ALT<2.5X IUNL and creatinine<1.5X IUNL

          -  Pre-enrollment coagulation parameters (PT and PTT) must be ≤1.5X the IUNL

          -  Patients must agree to use a medically effective method of contraception during and
             for a period of three months after the treatment period. A pregnancy test will be
             performed on each premenopausal female of childbearing potential immediately prior to
             entry into the research study

          -  Patients must be able to understand and give written informed consent. Informed
             consent must be obtained at the time of patient screening

        Exclusion Criteria:

          -  Women who are pregnant or lactating.

          -  Women of childbearing potential and fertile men will be informed of the potential
             unknown risk of conception while participating in this research trial and will be
             advised that they must use effective contraception during and for a period of three
             months after the treatment period

          -  Patients with significant intercurrent medical or psychiatric conditions that would
             place them at increased risk or affect their ability to receive or comply with
             treatment or post-treatment clinical monitoring

          -  Patients with radiological evidence of leptomeningeal disease

          -  Patients with history of allergic reaction to CTX

          -  Patients who completed chemo/RT less than 6 months prior to enrollment

          -  Patients who have not failed standard Stupp protocol
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Progression Free Survival (PFS)
Time Frame:6 months
Safety Issue:
Description:The 6-month PFS will be estimated by calculating the proportion of patients who are alive at 6 months from treatment commencement and are progression-free.

Secondary Outcome Measures

Measure:Composite overall response rate (CORR) through the Response Evaluation Criteria In Solid Tumors (RECIST)
Time Frame:6 months
Safety Issue:
Description:Subjects will be classified according to the RECIST criteria, which is a composite of MRI changes, clinical response and changes in steroid use.
Measure:Toxicities graded according to the NCI Common Toxicity Criteria (CTCAE) version 4.03
Time Frame:6 months
Safety Issue:
Description:Toxicities will be tabulated and graded according to the NCI Common Toxicity Criteria (CTCAE) version 4.03

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Northwell Health

Last Updated